Do you want to read an article? Please log in or register.
Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course.
Multiple Sclerosis
Related content
SPECIAL REPORT
Multiple Sclerosis
Vaccination Readiness in Multiple Sclerosis
Multiple Sclerosis
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N, MSBase Study Group
doi: 10.1001/jama.
Multiple Sclerosis
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Ther Adv Neurol Disord
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F, ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG).
doi: 10.1177/17562864211039648
Multiple Sclerosis
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
Cochrane Database Syst Rev.
Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G
doi: 10.1002/
Multiple Sclerosis
Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis
Mult Scler.
Sotirchos ES, Gonzalez-Caldito N, Dewey BE, Fitzgerald KC, Glaister J, Filippatou A, Ogbuokiri E, Feldman S, Kwakyi O, Risher H, Crainiceanu C, Pham DL, Van Zijl PC, Mowry EM, Reich DS, Prince JL, Calabresi PA, Saidha S
doi: 10.1177/
RECOMMENDED
Multiple Sclerosis
The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Brain.
Sorensen PS, Sellebjerg F, Hartung HP, Montalban X, Comi G, Tintoré M
doi: 10.1093/brain/awaa145.
SPECIAL REPORT
Multiple Sclerosis
Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis
World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application
Mult Scler.
McDonell J, Costello K, Laurson-Doube J, Rijke N, Giovannoni G, Banwell B, Baneke P
doi: 10.1177/1352458519898340.
RECOMMENDED
Multiple Sclerosis
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis
doi: 10.1001/jamaneurol.2018.4905.